Clinical Trials Browser

Phase 2 × Uterine Cervical Neoplasms × tislelizumab × Clear all

NCT04693234 2025-04-27

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

Phase 2 Completed

178 enrolled 26 charts

Uterine Cervical Neoplasms

NCT05588219 2023-11-24

Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Phase 2 Unknown

Uterine Cervical Neoplasms

NCT06039891 2023-09-15

Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer

Phase 2 Not yet recruiting

Uterine Cervical Neoplasms

NCT05247619 2022-07-15

A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 2 Unknown

Uterine Cervical Neoplasms